EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections

Christian Roehrig iD, Markus Huemer iD, Dominique Lorgé, Fabienne Arn, Nadine Heinrich, Lavanja Selvakumar, Lynn Gasser, Patrick Hauswirth, Chun-Chi Chang, Tiziano A Schweizer, Fritz Eichenseher, Steffi Lehmann und 2 weitere

mBio · 2024

DOI: 10.1128/mbio.02540-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Christian Roehrig und 13 weiteren Autor:innen. Beteiligte Einrichtung: Micreos Pharmaceuticals AG, Baar, Zug, Switzerland. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Sepsis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the most pressing challenges of our era is the rising occurrence of bacteria that are resistant to antibiotics. Staphylococci are prominent pathogens in humans, which have developed multiple strategies to evade the effects of antibiotics. Infections caused by these bacteria have resulted in a high burden on the health care system and a significant loss of lives. In this study, we have successfully engineered lytic enzymes that exhibit an extraordinary ability to eradicate staphylococci. Our findings substantiate the importance of meticulous lead candidate selection to identify therapeutically promising peptidoglycan hydrolases with unprecedented activity. Hence, they offer a promising new avenue for treating staphylococcal infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsSepsisHumansAnimalsMiceStaphylococcus aureusPeptidoglycanZebrafishAnti-Bacterial AgentsStaphylococcusN-Acetylmuramoyl-L-alanine Amidase

Stichwörter der Autor:innen

MRSAStaphylococcus aureusantibiotic resistanceantibioticsbacteremiabacteriophageendolysinpeptidoglycan hydrolaseprotein therapeuticsstaphylococci

Substanzen

PeptidoglycanAnti-Bacterial AgentsN-Acetylmuramoyl-L-alanine Amidase

Autor:innen und Institutionen

  • Micreos Pharmaceuticals AG, Baar, Zug, Switzerland.
  • Micreos GmbH, Wädenswil, Zurich, Switzerland.
  • Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences (ZHAW), Wädenswil, Zurich, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

ORCID-Profile: Christian Roehrig, Markus Huemer, Annelies S Zinkernagel

Zitieren

APA

Roehrig, C., Huemer, M., Lorgé, D., Arn, F., Heinrich, N., Selvakumar, L., Gasser, L., Hauswirth, P., Chang, C. C., Schweizer, T. A., Eichenseher, F., Lehmann, S., Zinkernagel, A. S., & Schmelcher, M. (2024). MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections. mBio. https://doi.org/10.1128/mbio.02540-23

Vancouver

Roehrig C, Huemer M, Lorgé D, Arn F, Heinrich N, Selvakumar L, et al. MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections. mBio. 2024. doi:10.1128/mbio.02540-23

BibTeX
@article{Roehrig2024,
  author = {Roehrig, Christian and Huemer, Markus and Lorgé, Dominique and Arn, Fabienne and Heinrich, Nadine and Selvakumar, Lavanja and Gasser, Lynn and Hauswirth, Patrick and Chang, Chun-Chi and Schweizer, Tiziano A and Eichenseher, Fritz and Lehmann, Steffi and Zinkernagel, Annelies S and Schmelcher, Mathias},
  title = {MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.02540-23}
}
Kostenlos starten →